Drug intelligence / Profile preview

JZP898

Development stage: Phase 1
Lead developer: Jazz Pharmaceuticals
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

JZP898, also known as WTX-613, is a conditionally-activated interferon alpha (IFNα) INDUKINE molecule. Originally developed by Werewolf Therapeutics, exclusive global rights were licensed to Jazz Pharmaceuticals for development in oncology. This investigational immunotherapy is designed to be activated specifically within the tumor microenvironment, aiming to enhance anti-tumor activity while minimizing systemic toxicities associated with conventional interferon alpha therapies. It is currently undergoing Phase 1 clinical trials for advanced or metastatic solid tumors and lymphoma.

Other names: Interferon alpha (IFNα) INDUKINE moleculeconditionally activated interferon alpha (IFNα) therapeutic

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on JZP898.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JZP898.

Explore the full profile